

CellaVision presents the Interim report for the first quarter of 2022, on May 10, at 11:00 CEST

CellaVision AB (publ) will publish the Interim report for the first quarter, on May 10, 2022 at 7:20 CEST. The report will be available at www.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where Simon Østergaard, President & CEO, will present and comment the report.

The presentation will be in English via a conference call or audio webcast:

<https://tv.streamfabriken.com/cellavision-q1-2022>

Phone number for the conference:

SE: +46 8 50 558 368

UK: +44 33 33 009 261

US: +1 64 67 224 904

No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time to facilitate a timely start.

Contact

Adele Horn

Corporate Communications & Investor Relations

Direct: +46 (0) 464 602 604

Mobile: +46 (0) 722 065 088

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 17 local market support organizations covering more than 40 countries. In 2021, sales were SEK 566 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Attachments

[CellaVision presents the Interim report for the first quarter of 2022, on May 10, at 11:00 CEST](#)